undamentalytics Newsletter
Sign in

Genedx Holdings Corp. (WGS) stock

Add to watchlist

Add holding +

NASDAQ: WGS Nasdaq Health Care Technology Next results ~November 9, 2026

C Fundamentals grade

Genedx Holdings Corp. is a US-listed company in the health care technology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$24

Valuation models combined (3)

Base case. Range ~$14–$33. Weighted average of 3 models (forward price-to-earnings vs peers, forward price-to-sales vs peers, revenue-to-maturity model).

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Genedx Holdings Corp. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders3 buying, 4 selling34 purchases and 105 sales by directors and officers, last 12 monthsInsider trades
  • Funds137 adding, 127 cuttingOf 59 active managers that changed their stake, 25 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Genedx Holdings files

Where Genedx stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $454m, up 25.4% on a year earlier, slower than the 34.1% growth a quarter earlier. That growth ranks 1 of 15 among the health care technology companies we cover. Free-cash-flow margin fell to -16.7% from 0.2% a year earlier. Operating margin narrowed to -20.3% from 1.5%. The diluted share count is up 2.6% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 3 of our 6 financial-health checks. Our revenue-to-maturity cash-flow model value is $32.64 a share, against a share price of $68.84.

Source: 10-Q filed August 3, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Genedx Holdings Corp.'s trailing-twelve-month revenue grew 25.4% year on year, with a free-cash-flow margin of -16.7%. Where it stands out: revenue growth of 25.4% ranks 5 of 23 health care technology companies we cover. Where it lags: change in growth rate of -8.7pp ranks 19 of 23 health care technology companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 105% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 25.4% over the last 12 months, against a median of 8.8% for health care technology companies we cover.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 8.6% over 90 days.

Things to watch

  • Growth slowing. The growth rate is 8.7 points lower than a quarter earlier.
  • Loss-making. Operating margin is -20.3%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 21.8 points on a year ago.
  • Burning cash. Free cash flow was -16.7% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 2.6% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 88% and a beta of 1.6 against the S&P 500.

Latest results: FY2026 Q2

Filed August 3, 2026
Earnings per share
$0.01 against an average estimate of -$0.19: beat by 105.3%
Revenue
$114m, up 11.4% on a year earlier
Share reaction
+8.9% in the first session after the results on August 3, 2026, against +3.3% for the S&P 500
Next report
November 9, 2026; average EPS estimate $0.07

Genedx Holdings' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-7.2%
  • 1 week+4.6%
  • 1 month-12.3%
  • This year-50.7%
  • 1 year-53.2%
  • 5 years-76.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$454M
Operating margin
-20.3%
Net margin
-23.4%
EPS (TTM, diluted)
$-3.68

Growth

Revenue growth
+25.4%
Change in growth rate
−8.7 pts
Share count change
+2.6%

Cash

Free cash flow (TTM)
-$75.8M
FCF margin
-16.7%
Stock pay % of revenue
7.9%

Earnings

Last results
August 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Genedx Holdings Corp. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Genedx Holdings Corp. as an operating company, with every model that fits that kind of business. Cost of equity 10.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.25 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$2.1 ~$0.1–$3.4 Left out: out of range vs price (0.03x)
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$14 ~$11–$21 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$27 ~$23–$94 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$33 ~$25–$42 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$24 ~$14–$33 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Genedx Holdings Corp. with Health Care Technology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$364.32$147.18$8.71$2.75$76.86$130.06$64.09
Market value$169.9bn$1.4bn$89m$67m$2.1bn$3.7bn$1.9bn
+ Net debt (− = net cash)−$87m−$390m−$113m−$43m−$29m−$50m$40m
Enterprise value$169.9bn$1.1bn−$24m$23m$2.0bn$3.7bn$1.9bn
Multiples
Price / sales n/m6.8x0.4x0.3x6.8x8.7x4.1x
Price / earnings ———————
Price / free cash flow —————n/m—
EV / EBITDA ———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

16 /100

Weak moat

How hard Genedx Holdings's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -26.1% of total assets over 6 years.

  • Pricing power 4 / 20

    Gross margin has been a median 34.6%, moving by 34.9 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -104.9%; its worst year was -238.6%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 1 of 5 years, at a median -39.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (20 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $123m and EPS of $0.07 (range $0.07 to $0.08) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.13 −91% $482m +13%
Next $1.20 +812% $599m +24%

Next year's EPS estimate has moved +8.6% in 90 days, across 7 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −306.2% on 90 days ago. In the last 30 days, 3 analysts raised Genedx Holdings Corp.'s forecast and 2 cut it.

Consensus EPS forecast Genedx Holdings Corp., last 90 days
−$0.50 $0.00 $0.50 $1.00 $1.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.06 Current fiscal year, 60 days ago: $0.13 Current fiscal year, 30 days ago: $0.13 Current fiscal year, 7 days ago: $0.13 Current fiscal year, Now: $0.13 $0.13 Next fiscal year, 90 days ago: $1.10 Next fiscal year, 60 days ago: $1.17 Next fiscal year, 30 days ago: $1.17 Next fiscal year, 7 days ago: $1.20 Next fiscal year, Now: $1.20 $1.20

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.06$1.10
60 days ago $0.13$1.17
30 days ago $0.13$1.17
7 days ago $0.13$1.20
Now $0.13$1.20

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.19 $0.01 +105.3%
Mar 2026 −$0.02 −$0.28 −1407.8%
Dec 2025 $0.12 $0.14 +16.7%
Sept 2025 $0.42 $0.49 +15.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

8 analysts, Oct 2026
Buy8100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026178
  2. Sep 2026178
  3. Aug 2026189
  4. Jul 2026189

Counts of recommendations published by analysts covering Genedx Holdings Corp., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
38.6%
of tradable shares
Days to cover
7.23
at average volume
Short interest, 1 month
+2%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
7.7%
of shares
Employees
1,300
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months −53.2%

$136.91 on October 31, 2025 to $64.09

ThenNowEffect
Revenue (last 12 months) $362m $454m +25.4%
P/S multiple 10.7x 4.1x −61.7%
Share count 28m 29m −2.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
WGS−60%−94%−68%+2695%+69%−51%
Industry peers (median)−9%−60%−16%−24%−28%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
WGS33%25%33%75%58%18%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
WGS−83%−95%−93%−33%−52%−75%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 4, 2020: 100% from February 12, 2021 to November 13, 2023. Getting back needed a 68588% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$34.51 – $167.51
From 52-week high
−61.7%
vs 50-day average
−18.4%
vs 200-day average
−10.6%
Volatility (1 year)
88%
Beta vs S&P 500
1.56

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±26.4%
After a week
6 up, 6 down
typical move ±28.7%
After a month
6 up, 6 down
typical move ±33.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 3, 2026 +8.9% +3.3% +19.6% +30.3%
May 4, 2026 −47.2% +0.4% −39.4% −18.9%
February 23, 2026 −1.7% −0.3% −9.6% −16.3%
January 12, 2026 −18.9% 0.0% −26.4% −32.5%
October 28, 2025 +0.8% +0.3% +6.8% +26.7%
July 29, 2025 +21.9% −0.4% +25.6% +52.1%
April 30, 2025 −46.7% +0.7% −51.0% −39.1%
February 18, 2025 +45.8% +0.5% +25.5% +27.6%
January 13, 2025 −19.4% +0.3% −16.8% −20.6%
October 29, 2024 +48.4% −0.1% +33.5% +41.7%
July 30, 2024 −2.9% +1.1% −14.5% −5.9%
April 29, 2024 +54.1% −1.2% +76.2% +90.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Genedx Holdings Corp. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Genedx Holdings Corp.
$200M $300M $400M $500M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $206.5M Revenue (TTM), FY23 Q4: $202.6M Revenue (TTM), FY24 Q1: $221.8M Revenue (TTM), FY24 Q2: $243.7M Revenue (TTM), FY24 Q3: $267.2M Revenue (TTM), FY24 Q4: $305.5M Revenue (TTM), FY25 Q1: $330.1M Revenue (TTM), FY25 Q2: $362.3M Revenue (TTM), FY25 Q3: $402.2M Revenue (TTM), FY25 Q4: $427.5M Revenue (TTM), FY26 Q1: $442.7M Revenue (TTM), FY26 Q2: $454.4M $454.4M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $206.5M
FY23 Q4 $202.6M
FY24 Q1 $221.8M
FY24 Q2 $243.7M
FY24 Q3 $267.2M
FY24 Q4 $305.5M
FY25 Q1 $330.1M
FY25 Q2 $362.3M
FY25 Q3 $402.2M
FY25 Q4 $427.5M
FY26 Q1 $442.7M
FY26 Q2 $454.4M
Revenue growth, TTM YoY Genedx Holdings Corp.
-20% 0% 20% 40% 60% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -10.7% Revenue growth, TTM YoY, FY23 Q4: -13.7% Revenue growth, TTM YoY, FY24 Q1: -0.9% Revenue growth, TTM YoY, FY24 Q2: 3.1% Revenue growth, TTM YoY, FY24 Q3: 29.4% Revenue growth, TTM YoY, FY24 Q4: 50.8% Revenue growth, TTM YoY, FY25 Q1: 48.8% Revenue growth, TTM YoY, FY25 Q2: 48.7% Revenue growth, TTM YoY, FY25 Q3: 50.5% Revenue growth, TTM YoY, FY25 Q4: 40.0% Revenue growth, TTM YoY, FY26 Q1: 34.1% Revenue growth, TTM YoY, FY26 Q2: 25.4% 25.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -10.7%
FY23 Q4 -13.7%
FY24 Q1 -0.9%
FY24 Q2 3.1%
FY24 Q3 29.4%
FY24 Q4 50.8%
FY25 Q1 48.8%
FY25 Q2 48.7%
FY25 Q3 50.5%
FY25 Q4 40.0%
FY26 Q1 34.1%
FY26 Q2 25.4%
Operating margin (TTM) Genedx Holdings Corp.
-300% -200% -100% 0% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -232.4% Operating margin (TTM), FY23 Q4: -89.2% Operating margin (TTM), FY24 Q1: -60.4% Operating margin (TTM), FY24 Q2: -38.1% Operating margin (TTM), FY24 Q3: -21.6% Operating margin (TTM), FY24 Q4: -7.6% Operating margin (TTM), FY25 Q1: -4.3% Operating margin (TTM), FY25 Q2: 1.5% Operating margin (TTM), FY25 Q3: 2.5% Operating margin (TTM), FY25 Q4: -3.1% Operating margin (TTM), FY26 Q1: -14.9% Operating margin (TTM), FY26 Q2: -20.3% -20.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -232.4%
FY23 Q4 -89.2%
FY24 Q1 -60.4%
FY24 Q2 -38.1%
FY24 Q3 -21.6%
FY24 Q4 -7.6%
FY25 Q1 -4.3%
FY25 Q2 1.5%
FY25 Q3 2.5%
FY25 Q4 -3.1%
FY26 Q1 -14.9%
FY26 Q2 -20.3%
FCF margin (TTM) Genedx Holdings Corp.
-150% -100% -50% 0% 50% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -106.5% FCF margin (TTM), FY23 Q4: -91.5% FCF margin (TTM), FY24 Q1: -66.1% FCF margin (TTM), FY24 Q2: -39.5% FCF margin (TTM), FY24 Q3: -22.4% FCF margin (TTM), FY24 Q4: -11.1% FCF margin (TTM), FY25 Q1: -4.0% FCF margin (TTM), FY25 Q2: 0.2% FCF margin (TTM), FY25 Q3: 3.8% FCF margin (TTM), FY25 Q4: 3.3% FCF margin (TTM), FY26 Q1: -6.5% FCF margin (TTM), FY26 Q2: -16.7% -16.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -106.5%
FY23 Q4 -91.5%
FY24 Q1 -66.1%
FY24 Q2 -39.5%
FY24 Q3 -22.4%
FY24 Q4 -11.1%
FY25 Q1 -4.0%
FY25 Q2 0.2%
FY25 Q3 3.8%
FY25 Q4 3.3%
FY26 Q1 -6.5%
FY26 Q2 -16.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 196 179 212 235 203 305 428 454
Gross profit 83 4 −17 −27 90 194 298 315
EBITDA −24 −230 −424 −618 −161 −15 −3 −81
Operating income −30 −242 −446 −668 −181 −23 −13 −92
Net income −30 −241 −245 −549 −176 −52 −21 −106
Diluted EPS −$2904616.00 −$517396.00 −$24.97 −$53.63 −$7.23 −$1.94 −$0.73 −$3.68
Growth (year on year)
Revenue — −8.6% +18.3% +10.6% −13.7% +50.8% +40.0% +25.4%
EBITDA — — — — — — — −666.5%
Margins
Gross margin 42.2% 2.2% −7.8% −11.4% 44.4% 63.6% 69.7% 69.4%
EBITDA margin −12.2% −128.4% −200.0% −263.2% −79.4% −5.0% −0.8% −17.9%
Operating margin −15.5% −134.9% −210.3% −284.5% −89.2% −7.6% −3.1% −20.3%
Net margin −15.1% −134.6% −115.6% −233.9% −86.8% −17.1% −4.9% −23.4%
Free-cash-flow margin −15.6% −65.4% −94.2% −139.0% −91.5% −11.1% 3.3% −16.7%
Cash flow
Cash from operations −19 −93 −190 −319 −180 −28 33 −49
Capital spending 12 24 9 7 5 5 19 27
Free cash flow −31 −117 −200 −326 −185 −34 14 −76
Stock-based pay 5 120 219 42 −0 9 32 36
Free cash flow after stock pay −36 −237 −419 −368 −185 −43 −18 −112
Balance sheet
Cash 115 108 401 124 100 85 105 60
Total debt 0 21 11 11 56 56 55 100
Net debt (negative = net cash) −115 −87 −390 −113 −43 −29 −50 40
Diluted shares — 466m 10m 10m 24m 27m 29m 29m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 6 checks passed · June 30, 2026
What it owns · $481m
Short-term assets $246mLonger-term assets $235m
What it owes, and who funded it · $481m
Short-term liabilities $75mLonger-term liabilities $163mShareholders' equity $244m
  • Short-term assets cover short-term liabilities $246m of assets due within a year against $75m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $246m short-term assets against $163m of longer-dated liabilities.
  • More cash than debt $60m of cash against $97m of debt.
  • Debt below 40% of shareholders' equity Debt is 40% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 3% to 40% over five years.
  • A year's operating cash flow covers at least 20% of debt −$49m of operating cash flow against $97m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Genedx Holdings Corp.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+2.6%
year over year
R&D spending
18.4%
of revenue
Days sales outstanding
67 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care technology
Last 12 months unless stated WGS PHR HSTM DOCS HCAT GDRX Median
Revenue, last 12 months $454m $508m $321m $656m $292m $785m $292m
Revenue growth, last 12 months 25.4% 12.9% 8.8% 11.2% −7.5% −1.8% 8.8%
Revenue growth, 3-year average 24.3% 16.7% 5.4% 14.5% 0.9% 1.8% 0.8%
Revenue growth, latest quarter 11.4% 10.4% 12.5% 7.3% −12.7% −1.3% 7.4%
Gross margin 69.4% — 59.1% 88.1% — — 58.6%
Operating margin −20.3% 2.5% 8.0% 29.6% −84.4% 9.5% −12.5%
Operating margin, 3-year average −19.0% −9.5% 7.3% 35.4% −48.1% 5.6% −18.8%
Net margin −23.4% 2.1% 6.6% 25.5% −90.6% 2.1% −12.5%
Cash from operations / revenue −10.7% 18.0% 22.4% 46.7% 9.7% 25.7% 9.7%
Free-cash-flow margin −16.7% 15.9% 21.7% 46.7% 9.2% 25.1% 9.2%
Free-cash-flow margin, 3-year average −18.7% 7.8% 21.4% 43.6% 1.7% 21.7% 8.2%
Stock pay / revenue 7.9% 11.7% 2.7% 20.8% 6.0% 9.7% 9.5%
Change in share count 2.6% 5.5% −3.3% −2.5% 10.3% −9.8% 2.9%

Median of all 23 companies we cover in health care technology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

23 health care technology companies
Measure Company Peer median Rank
Revenue growth Growth 25.4% 8.8% 5 of 23
Change in growth rate Growth -8.7pp -0.3pp 19 of 23
Gross margin Profitability 69.4% 58.2% 5 of 14
Operating margin Profitability -20.3% -6.6% 14 of 22
Net margin Profitability -23.4% -12.5% 13 of 23
Free-cash-flow margin Cash generation -16.7% 10.6% 16 of 22
Stock pay as % of revenue Cash generation 7.9% 9.7% 10 of 22
Long-term debt as % of assets Balance sheet 20.1% 20.1% 8 of 15
Change in share count Balance sheet 2.6% 2.6% 10 of 19
Days sales outstanding Balance sheet 67 days 58 days 13 of 21

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Gene Dx $423M 99.0% ▲ 40.0%
All Other Segments $4.5M 1.0% ▲ 41.0%
Products and services
Line of business Revenue Share YoY
Diagnostic Test $417M 97.1% ▲ 37.9%
Diagnostic Test Third Party Insurance $345M 82.9% ▲ 47.1%
Diagnostic Test Institutional Customers $70.1M 16.8% ▲ 7.6%
Other $10.9M 2.5% ▲ 230.1%
Diagnostic Test Self Pay $1.4M 0.3% ▼ 41.9%

From Genedx Holdings Corp.'s 10-K filed February 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2.2B
Institutions reporting
223
Shares held vs prior quarter
▲ 2.1%
Positions opened / closed
53 / 69

Top buyers and sellers, Q2 2026: 137 institutions bought and 127 sold ; the biggest buyer was Corvex Management LP (+1.6M shares) and the biggest seller Westfield Capital Management Co LP (−1.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Corvex Management LP $328M 4.8M 15.0% ▲ 48.2%
Casdin Capital, LLC $254M 3.7M 11.6% ▲ 23.3%
Blackrock, Inc. $117M 1.7M 5.4% ▲ 10.0%
Goldman Sachs Group Inc $115M 1.7M 5.2% ▲ 25.1%
ARK Investment Management LLC $111M 1.6M 5.1% ▲ 21.6%
William Blair Investment Management, LLC $96.2M 1.4M 4.4% ▲ 80.7%
Morgan Stanley $67.8M 988K 3.1% ▲ 85.7%
Vanguard Capital Management LLC $60.3M 879K 2.8% ▲ 2.4%
Citadel Advisors LLC $59.4M 865K 2.7% ▲ 33.7%
First Light Asset Management, LLC $53.8M 784K 2.5% ▲ 222.7%
Deep Track Capital, LP $48.1M 700K 2.2% New
Sumitomo Mitsui Trust Group, Inc. $45.8M 667K 2.1% ▲ 5.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Genedx Holdings Corp.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $107M 34 trades by 3 insiders, last 12 months Insider sales History → $21.5M 105 trades by 4 insiders · 2% under pre-set plans
Net ▲ $85.1M net buying
Insider Date Trade Shares Price Value
Feeley Kevin CHIEF FINANCIAL OFFICER September 16, 2026 Sell 52 $95.41 $4,961
Feeley Kevin CHIEF FINANCIAL OFFICER September 16, 2026 Sell 1,470 $98.27 $144,457
Feeley Kevin CHIEF FINANCIAL OFFICER September 16, 2026 Sell 541 $96.90 $52,423
Feeley Kevin CHIEF FINANCIAL OFFICER September 16, 2026 Sell 1,079 $99.00 $106,821
Feeley Kevin CHIEF FINANCIAL OFFICER September 16, 2026 Sell 586 $94.26 $55,236
Stueland Katherine CHIEF EXECUTIVE OFFICER September 16, 2026 Sell 3,039 $99.00 $300,861
Stueland Katherine CHIEF EXECUTIVE OFFICER September 16, 2026 Sell 1,648 $94.26 $155,340
Stueland Katherine CHIEF EXECUTIVE OFFICER September 16, 2026 Sell 148 $95.41 $14,121
Stueland Katherine CHIEF EXECUTIVE OFFICER September 16, 2026 Sell 1,525 $96.90 $147,772
Stueland Katherine CHIEF EXECUTIVE OFFICER September 16, 2026 Sell 4,141 $98.27 $406,936
Feeley Kevin CHIEF FINANCIAL OFFICER September 9, 2026 Sell 1,285 $84.22 $108,223
Stueland Katherine CHIEF EXECUTIVE OFFICER September 9, 2026 Sell 3,692 $84.22 $310,940

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 16, 2026 estimated from the company's past filing pattern, not announced

  • August 3, 2026
  • May 4, 2026
  • February 23, 2026
  • January 12, 2026
  • October 28, 2025
  • July 29, 2025

Recent SEC filings

Data status

When each part of this page on Genedx Holdings Corp. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Genedx Holdings Corp. in brief

What does Genedx Holdings Corp. do?
Genedx Holdings Corp. is a US-listed company in the health care technology industry. Its financial year ends in December.
What is Genedx Holdings Corp.'s stock ticker?
Genedx Holdings Corp. trades under the ticker WGS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Genedx Holdings Corp.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Genedx Holdings Corp. reported revenue of $454M, 25.4% higher than a year earlier, according to its SEC filings.
What is Genedx Holdings Corp.'s free cash flow?
Genedx Holdings Corp.'s free-cash-flow margin is -16.7% of revenue over the trailing twelve months, ranking 16 of the 22 health care technology companies we cover.
Who are Genedx Holdings Corp.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Corvex Management LP, Casdin Capital, LLC and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Genedx Holdings Corp.'s market cap?
On November 2, 2026, Genedx Holdings Corp.'s market capitalisation was about $1.9B and net debt of $39.7M. Market figures come from third-party market data and may be delayed.
How much debt does Genedx Holdings Corp. have?
Genedx Holdings Corp.'s debt-to-equity ratio is 39.7%, from its latest balance sheet (2.8% five years earlier). The financial health section below sets out its other solvency checks.
Who are Genedx Holdings Corp.'s competitors?
In our Health Care Technology peer group, the companies closest to Genedx Holdings Corp. are Phreesia, Inc., Healthstream Inc, Doximity, Inc., Health Catalyst, Inc. and Goodrx Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Genedx Holdings Corp.'s.
Are insiders buying or selling Genedx Holdings Corp. stock?
Over the last 12 months, Genedx Holdings Corp.'s directors and officers reported 34 open-market purchases and 105 sales on Form 4. The insider trading page charts every trade.
When is Genedx Holdings Corp.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Genedx Holdings Corp. announces its own schedule.